Background: The challenge posed by the COVID-19 pandemic may represent an overwhelmingly stressful event for ankylosing spondylitis (SpA) patients and impact their treatment adherence. In response to ...

Correspondence to Martin Aringer, Medicine III, University Medical Center and Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden D-01307, Germany; martin.aringer{at}uniklinikum-dresden.de; Dr ...

The Parker Institute, Frederiksberg Hospital, Copenhagen University Hospital, The Capital Region of Denmark, DK-2000 Copenhagen F, Denmark Søren Torp-Pedersen, The Parker Institute, Frederiksberg ...

Correspondence to Professor Mary K Crow, Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY 10021, USA; crowm{at}hss.edu Research elucidating the pathogenesis of ...

Background Since the publication of the 2011 European Alliance of Associations for Rheumatology (EULAR) recommendations for patient research partner (PRP) involvement in rheumatology research, the ...

Objective Autoantibodies against antigens carrying distinct post-translational modifications (PTMs), such as citrulline, homocitrulline or acetyllysine, are hallmarks of rheumatoid arthritis (RA). The ...

Objective Calcium pyrophosphate deposition (CPPD) disease is prevalent and has diverse presentations, but there are no validated classification criteria for this symptomatic arthritis. The American ...

Correspondence to Professor Erwin F Wagner, Department of Dermatology and Department of Laboratory Medicine, Medical University of Vienna, Wien, Austria; erwin.wagner{at}meduniwien.ac.at Objectives ...

The therapeutic management of Sjögren syndrome (SjS) has not changed substantially in recent decades: treatment decisions remain challenging in clinical practice, without a specific therapeutic target ...

Objective Recent large-scale randomised trials demonstrate that immunomodulators reduce cardiovascular (CV) events among the general population. However, it is uncertain whether these effects apply to ...

Background Despite treatment according to the current management recommendations, a significant proportion of patients with rheumatoid arthritis (RA) remain symptomatic. These patients can be ...

Objectives MAXIMISE (Managing AXIal Manifestations in psorIatic arthritis with SEcukinumab) trial was designed to evaluate the efficacy of secukinumab in the management of axial manifestations of ...